Managing resistance in chronic myeloid leukemiaROYCHOWDHURY, Sameek; TALPAZ, Moshe.Blood reviews. 2011, Vol 25, Num 6, pp 279-290, issn 0268-960X, 12 p.Article

Chronic Myelogenous LeukemiaKANTARJIAN, Hagop M; TALPAZ, Moshe.Hematology/oncology clinics of North America. 2004, Vol 18, Num 3, issn 0889-8588, 274 p.Serial Issue

Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibitionTALPAZ, Moshe.Seminars in hematology. 2001, Vol 38, Num 3, pp 22-27, issn 0037-1963, SUP8Article

STI-571 in chronic myelogenous leukaemiaTSAO, Anne S; KANTARJIAN, Hagop; TALPAZ, Moshe et al.British journal of haematology. 2002, Vol 119, Num 1, pp 15-24, issn 0007-1048, 10 p.Article

Imatinib mesylate: Clinical results in philadelphia chromosome-positive leukemiasKANTARJIAN, Hagop M; TALPAZ, Moshe.Seminars in oncology. 2001, Vol 28, Num 5, pp 9-18, issn 0093-7754, SUP17Article

Chronic myelogenous leukemiaKALIDAS, Mamta; KANTARJIAN, Hagop; TALPAZ, Moshe et al.JAMA, the journal of the American Medical Association. 2001, Vol 286, Num 8, pp 895-898, issn 0098-7484Article

The BCR gene and philadelphia chromosome-positive leukemogenesisLAURENT, Eunice; TALPAZ, Moshe; KANTARJIAN, Hagop et al.Cancer research (Baltimore). 2001, Vol 61, Num 6, pp 2343-2355, issn 0008-5472Article

Natural history and staging of chronic myelogenous leukemiaCORTES, Jorge.Hematology/oncology clinics of North America. 2004, Vol 18, Num 3, issn 0889-8588, viii, 569-584 [17 p.]Article

Autocrine interleukin-6 production in renal cell carcinoma: Evidence for the involvement of p53ANGELO, Laura S; TALPAZ, Moshe; KURZROCK, Razelle et al.Cancer research (Baltimore). 2002, Vol 62, Num 3, pp 932-940, issn 0008-5472Article

Modulation of cellular signaling pathways: Prospects for targeted therapy in hematological malignanciesRAVANDI, Farhad; TALPAZ, Moshe; ESTROV, Zeev et al.Clinical cancer research. 2003, Vol 9, Num 2, pp 535-550, issn 1078-0432, 16 p.Article

Current therapy of chronic myelogenous leukemiaGARCIA-MANERO, Guillermo; TALPAZ, Moshe; KANTARJIAN, Hagop M et al.Internal medicine (Tokyo. 1992). 2002, Vol 41, Num 4, pp 254-264, issn 0918-2918Article

Animal models of chronic myelogenous leukemiaILARIA, Robert L.Hematology/oncology clinics of North America. 2004, Vol 18, Num 3, issn 0889-8588, vii, 525-543 [20 p.]Article

Cellular signalling pathways: New targets in leukaemia therapyRAVANDI, Farhad; TALPAZ, Moshe; KANTARJIAN, Hagop et al.British journal of haematology. 2002, Vol 116, Num 1, pp 57-77, issn 0007-1048Article

Autologous hematopoietic cell transplantation for chronic myelogenous leukemiaBHATIA, Ravi; MCGLAVE, Philip B.Hematology/oncology clinics of North America. 2004, Vol 18, Num 3, issn 0889-8588, xi, 715-732 [19 p.]Article

Immunity to chronic myelogenous leukemiaKURBEGOV, Dax; MOLLDREM, Jeffrey J.Hematology/oncology clinics of North America. 2004, Vol 18, Num 3, pp xi-xii, issn 0889-8588, 22 p.Article

Clinical significance of minimal residual disease in leukemia (Review)FADERL, Stefan; KANTARJIAN, Hagop M; TALPAZ, Moshe et al.International journal of oncology. 2000, Vol 17, Num 6, pp 1277-1287, issn 1019-6439Article

Clinical resistance to imatinib: mechanisms and implicationsHOCHHAUS, Andreas; HUGHES, Timothy.Hematology/oncology clinics of North America. 2004, Vol 18, Num 3, issn 0889-8588, ix, 641-656 [17 p.]Article

Philadelphia chromosome-positive leukemias: From basic mechanisms to molecular therapeuticsKURZROCK, Razelle; KANTARJIAN, Hagop M; DRUKER, Brian J et al.Annals of internal medicine. 2003, Vol 138, Num 10, pp 819-830, issn 0003-4819, 12 p.Article

Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cellsJOHNSON, Faye M; SAIGAL, Babita; TALPAZ, Moshe et al.Clinical cancer research. 2005, Vol 11, Num 19, pp 6924-6932, issn 1078-0432, 9 p., 1Article

Clonal evolution in chronic myelogenous leukemiaCORTES, Jorge; O'DWYER, Michael E.Hematology/oncology clinics of North America. 2004, Vol 18, Num 3, issn 0889-8588, x, 671-684 [15 p.]Article

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistanceKANTARJIAN, Hagop M; TALPAZ, Moshe; GILES, Francis et al.Annals of internal medicine. 2006, Vol 145, Num 12, pp 913-923, issn 0003-4819, 11 p.Article

Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemiaFADERL, Stefan; HARRIS, David; QUIN VAN et al.Blood. 2003, Vol 102, Num 2, pp 630-637, issn 0006-4971, 8 p.Article

Therapeutic choices in younger patients with chronic myelogenous leukemiaKANTARJIAN, Hagop M; GILES, Francis J; O'BRIEN, Susan et al.Cancer. 2000, Vol 89, Num 8, pp 1647-1658, issn 0008-543XArticle

Imatinib mesylate causes hypopigmentation in the skinTSAO, Anne S; KANTARJIAN, Hagop; CORTES, Jorge et al.Cancer. 2003, Vol 98, Num 11, pp 2483-2487, issn 0008-543X, 5 p.Article

Pilot study of low-dose Interleukin-11 in patients with bone marrow failureKURZROCK, Razelle; CORTES, Jorge; THOMAS, Deborah A et al.Journal of clinical oncology. 2001, Vol 19, Num 21, pp 4165-4172, issn 0732-183XArticle